IHL (ASX) General discussion

Originally posted by Jam_Man07: ↑

Couldn't agree more Tibbs, this story is just starting to warm up, we've seen experienced and respected fund manager Glen Poswell take a position in these guys, he's the first smart money at the table, I think plenty of others would be watching this closely, it has certainly traded like there is some serious accumulation going on. IHL has over $12m in the bank and no need for a capital raise anytime soon. What a good time to get set, or add to positions. Loads of news flow coming and exciting move into Psychedelics making it the only Psychedelic play on the asx. Remember Compass Pathways in the US is valued at $US1.3bn.

I think the move to 20c could be as quick as the Donald's recovery from COVID.

Exciting times to be a shareholder, glta!

Expand

Also worth remembering that Sud's 20c CMO Options expire Sep 2021. That's less than a year away now and with biotechs, it takes quite some time to get things going. It is imperative for the company to achieve several of its mid-term goals before that date and they are on track to do so.

Those also only vest if IHL trades at 20c or above for a minimum of 5 trading days or more. So we aren't talking a brief spike into 20c to get sold down. We are talking a re-rate that should take us well above 20c, where support can be found at the 20c or higher level when there is an inevitable euphoria and selloff stage. Combine this w/ the remainder of the Cannvalate Options expiring Dec this year at 6-14c strike and we have a massive incentive for management who already have enormous skin in the game.

TBI Human Trials are some time off due to COVID restrictions, and we likely wont see that trial get HREC and commence for months. Which is a shame as they were scheduled to run in a similar time to OSA but... COVID ruined that for us. TMJ we havent heard a peep out of besides it being in the preclinical stage because we have a lot on our plate at the moment and will probably come next year at some point.

Considering how long it has taken for the company to develop its trial protocols and work to the point of being on the cusp of commencing our first ever human trial at the Alfred and currently working on preclinical trials for ARDS and TBI, it is clear that this upcoming newsflow and trial commencement and results is the catalyst that should take us to the levels that are necessary for Sud's 20c options to vest.

Exciting times ahead.